Navigation Links
Elusys Awarded $68 Million Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection
Date:9/8/2011

PINE BROOK, N.J., Sept. 8, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a  biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection (IM). The five year contract, totaling up to $68.9 million, will support multiple animal efficacy studies as well as human safety studies to further demonstrate the utility of Anthim (ETI-204), the company's anti-toxin, to prevent disease and death from exposure to anthrax when administered intramuscularly before symptoms of disease are present.  Anthim is an anti-toxin that significantly increases survival in anthrax-infected animals and is a promising candidate for the treatment of anthrax infection in people following a biowarfare attack. Intramuscular injection allows for the rapid administration of a single-dose of anti-toxin to large numbers of people outside of a hospital or medical setting and will not require trained medical personnel, intravenous bags, sterile mixing and other preparations needed for intravenous administration.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/NY01624LOGO)

"Many more people can quickly receive prophylactic treatment against anthrax infection using intramuscular administration, particularly in an emergency setting before symptoms are present," said Elizabeth Posillico, PhD, President and Chief Executive Officer of Elusys. "In several  animal studies conducted to date, ETI-204 has demonstrated excellent efficacy and increased survival significantly when given in a single intramuscular dose. We are pleased to continue the advanced development of Anthim for prophylactic therapy against anthrax toxemia."  

Anthrax is a life-threatening infectious disease caused by the bacteria Bacillus anthracis and remains one of the nation's top biowarfare threats.
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
2. Elusys Presents Data From Anthim(R) Anthrax Anti-Toxin Studies at the HHS Stakeholders Workshop 2009 & BARDA Industry Day
3. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
4. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
5. Sanmina-SCI Kenosha, Wisconsin Facility Awarded ISO 13485 Certification for Medical Devices
6. Eurotech Awarded 1.5M USD Contract to Supply Embedded Computers for Medical Application
7. USANA Awarded the NutriSearch Gold Medal of Achievement™
8. Avaxia Biologics, Inc. Awarded BARDA Contract for Therapeutic Countermeasure to Help the Nation Respond to a Radiological Emergency
9. Inogen Awarded Department of Veterans Affairs Contract
10. Meaningful Use Certification Awarded to Press Ganeys Quality Performer(SM)
11. PCB Leader Mass Design Awarded Medical Device Manufacturing Certification ISO 13485:2003
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft tissue ... Phase 2 clinical trial.  This open-label study will assess ... (an investigational medication), in approximately 30 adults as first-line ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 is ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2
... Potential New Approach for the Treatment of Inflammatory ... ... Million Payment from Partner GlaxoSmithKline, MOUNTAIN VIEW, Calif., May 13 ... trial of CCX354, an,orally-available, novel small molecule compound designed to specifically,target ...
... FRANCISCO, Calif., May 12 Napo,Pharmaceuticals, Inc., (LSE: ... in collaboration with QualityMetric, Inc. describing the development,of ... Health-Related,Quality of Life (HR-QoL) aspects of chronic diarrhea ... Society for Pharmacoeconomics and,Outcomes Research (ISPOR) Annual Meeting ...
Cached Medicine Technology:ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 2ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 3ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 4ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354 5Napo Presents at ISPOR Meeting in Toronto 2
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Thousand of ... Medical Care recalled its GranuFlo and NaturaLyte dialysis concentrates ... underway in U.S. District Court, District of Massachusetts, Bernstein ... 20th, the Court has remanded a case filed by ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television host, ... 32nd Annual Miami Breast Cancer Conference planned and ... , shares that “a fast-growing, virulent” cancer in her ... not followed up her clean mammogram with an ultrasound. ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... is Hepatitis Awareness Month, HARRISBURG, Pa., May 19 ... discussed the importance of,Hepatitis disease awareness and vaccination during ... individuals are considered at high risk for Hepatitis B ... care insurance or ready,access to medical care," said Dr. ...
... Insurance among 52 Companies Recognized for Promoting Healthy ... ... The National Business Group on,Health, a national non-profit organization of ... promoting a,healthy workplace and encouraging a healthy lifestyle for its employees ...
... reliable genetic tests to guide lung cancer treatment has ... evaluated the ability of five high-risk genetic profiles, or ... in patients whose non-small cell lung cancer was caught ... at the American Thoracic Societys 2008 International Conference in ...
... Saliva Diagnostics and Dental ... Dental Care, WASHINGTON, May 19 The American Academy ... is,holding its 61st Annual Session this week in Washington, D.C. ... discuss the latest,advancements and research in pediatric oral health., ...
... May 19 On May 13, 2008, the Cancer,Prevention ... the FDA. This updates scientific information detailed in a,November ... FDA. It also,documents prior knowledge of the FDA and ... scientific basis of the 2008 Petition is detailed in ...
... CHATTANOOGA, Tenn., May 19 Shared Health, Inc., ... (HIE), and,Novo Innovations, the leading healthcare provider of ... to provide,improved data integration delivered to clinicians at ... deploying Novo agent software to enhance the clinical,interface ...
Cached Medicine News:Health News:PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors 2Health News:National Business Group on Health Honors Erie Insurance As One of Best Employers for Healthy Lifestyles 2Health News:National Business Group on Health Honors Erie Insurance As One of Best Employers for Healthy Lifestyles 3Health News:Will lung cancer recur? A genetic test may provide the answer 2Health News:2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements 2Health News:2008 American Academy of Pediatric Dentistry Annual Session Highlights Emerging Scientific Advancements 3Health News:Petition Seeking a Cancer Warning on Cosmetic Talc Powder Products 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 2Health News:Shared Health(R) and Novo Innovations Partner for Improved Information-Sharing of Clinical Health Records 3
... Thermovent® T helps provide protection to the exposed ... and extremely lightweight making it ideal for active ... high rate of heat and moisture recovery, it ... ,All HMEs and filters have ISO standard tapered ...
... viscosity and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
Inquire...
Medicine Products: